Oncternal Therapeutics Inc

-0.11 (-2.16%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)245.35M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$1.24 Million
Adjusted EPS-$0.11
See more estimates
10-Day MA$5.53
50-Day MA$6.93
200-Day MA$4.56
See more pivots

Oncternal Therapeutics Inc Stock, NASDAQ:ONCT

12230 El Camino Real, Suite 300, San Diego, California 92130
United States of America
Phone: +1.858.434.1113
Number of Employees: 14


Oncternal Therapeutics, Inc. engages in the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Its product pipeline include Cirmtuzumab, TK216, and ROR1 CAR-T. The company was founded by David F. Hale and James B. Breitmeyer in 1997 and is headquartered in San Diego, CA.